Biogroup bond debut shines in unsecured
Biogroup’s debut in the high yield bond market has become one of the tightest ever triple-C rated issues, validating the former loan-only company’s decision to turn to public markets to add subordination to the refinancing of its capital structure.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: